Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

May 21, 2024

BUY
N/A
1,381 Added 96.24%
2,816 $9,000
Q3 2023

Oct 30, 2023

BUY
N/A
1,381 Added 96.24%
2,816 $5,000
Q2 2023

May 21, 2024

SELL
N/A
-41 Reduced 2.78%
1,435 $4,000
Q2 2023

Jul 27, 2023

SELL
N/A
-41 Reduced 2.78%
1,435 $2,000
Q1 2023

May 21, 2024

BUY
N/A
369 Added 33.33%
1,476 $4,000
Q1 2023

Apr 27, 2023

BUY
N/A
369 Added 33.33%
1,476 $2,000
Q4 2022

May 21, 2024

BUY
$3.08 - $4.05 $3,409 - $4,483
1,107 New
1,107 $3,000
Q4 2022

Jan 31, 2023

BUY
$3.08 - $4.05 $3,409 - $4,483
1,107 New
1,107 $2,000

Others Institutions Holding ADGI

About Adagio Therapeutics, Inc.


  • Ticker ADGI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 108,831,000
  • Market Cap $505M
  • Description
  • Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's lead product candidate is the ADG20 (adintrevimab), a neutralizing antibody that is in Phase 3 clinical trials for the treatmen...
More about ADGI
Track This Portfolio

Track China Universal Asset Management Co., Ltd. Portfolio

Follow China Universal Asset Management Co., Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of China Universal Asset Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on China Universal Asset Management Co., Ltd. with notifications on news.